Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,381JPY
18 Aug 2017
Change (% chg)

¥-13 (-0.93%)
Prev Close
¥1,394
Open
¥1,384
Day's High
¥1,386
Day's Low
¥1,375
Volume
4,796,000
Avg. Vol
7,883,981
52-wk High
¥1,688
52-wk Low
¥1,332

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥2,857,045.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.46

Financials

  4503.T Industry Sector
P/E (TTM): 14.90 31.45 32.56
EPS (TTM): 92.68 -- --
ROI: 13.91 15.33 14.89
ROE: 15.50 16.35 16.13

BRIEF-Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan

* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan

Jul 31 2017

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

Jul 28 2017

BRIEF- Astellas Pharma to repurchase shares

* Says it will repurchase up to 50 million shares, representing 2.4 percent of outstanding

Jul 27 2017

BRIEF-Astellas announces wind-down of Agensys research operations

* Astellas announces wind-down of Agensys research operations

Jul 26 2017

BRIEF-U.S. FDA grants orphan-drug designation to Astellas

* U.S. FDA grants orphan-drug designation to Astellas for development of FLT3 inhibitor gilteritinib in acute myeloid leukemia Source text for Eikon: Further company coverage:

Jul 20 2017

BRIEF- Astellas Pharma submits supplemental new drug application for mirabegron for use in combination with solifenacin succinate 5 mg

* Says it announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency

Jun 29 2017

BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide

* Astellas and Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide in patients with non-metastatic castration-resistant prostate cancer

Jun 09 2017

BRIEF-Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​

* Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​

Jun 05 2017

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17

May 16 2017

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

May 10 2017

Earnings vs. Estimates